Skip to main content

Table 1 Clinical characteristics, therapeutic data and outcomes of the five patients

From: High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma

Patient

Gender

Age

Histopathology

Ann Arbor Stage

Primary refractorya

Lines of chemo before IT

PD-L1 inhibitor

PD-1 inhibitor

OS

Status

Cycle

Response

Duration

Cycle

Responseb

Duration

1

M

24y

NSHL

IVA

Yes

3 + Rad

8

PD

3 m

13

CR

28 m

72 m

Alive

2

F

36y

NSHL

IVB

Yes

3 + Rad

4

PD

3 m

12

CR

28 m

46 m

Alive

3

F

54y

NSHL

IIA

Yes

4 + Rad

4

PD

3 m

-

-

-

46 m

Dead

4

F

43y

MCHL

IIA

Yes

7

6

PD

4 m

6

CR

18 m

72 m

Alive

5

M

33y

NSHL

IVA

Yes

2

8

PD

5 m

11

PR

26 m

46 m

Alive

  1. Abbreviation: OS = overall survival; F = female; M = male; NSHL = nodular sclerosing Hodgkin lymphoma; MCHL = mixed cellularity Hodgkin lymphoma; IT = immunotherapy; Rad = radiation; CR = complete response; PR = partial response; PD = progressive disease
  2. aPrimary refractory was defined as end-of-treatment positron emission tomography-computed tomography (PET-CT) scan positive
  3. bPatient 1, 2 and 4 were in CR, patient 5 was in PR at the last assessment